Updates are available Correction dated 2025-09-13
Click to view Correction: https://doi.org/10.1007/s40744-025-00782-6
-
Authors
Youssef, Peter
Ciciriello, Sabina
Tahir, Talib
Leadbetter, Joanna
Butcher, Belinda
Calao, Miriam
Walsh, Nicole
O’Sullivan, Catherine
Smith, Tegan
Littlejohn, Geoffrey https://orcid.org/0000-0002-7896-055X
-
Funding
Funding for this research was provided by:
AbbVie Pty Ltd
- License Information
-
More Information
Article History
Received: 18 October 2024
Accepted: 12 December 2024
First Online: 6 January 2025
Change Date: 30 August 2025
Change Type: Update
Change Details: The original online version of this article was revised to correct MDA definition, Figure 1, few values in the text, Reference 2 and the Supplementary Material.
Change Date: 13 September 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40744-025-00782-6
Declarations
:
: Financial arrangements of the authors with companies whose products may be related to the present manuscript are listed, as declared by the authors. Peter Youssef: has received honoraria for lectures and consulting from AbbVie, AstraZeneca, Eli Lilly, Celltrion, Pfizer, Sandoz, Janssen, and Novartis. Sabina Ciciriello and Talib Tahir: Nothing to disclose. Belinda Butcher: Acts as a statistical consultant to many pharmaceutical and device companies, including those who manufacture products for RA. Joanna Leadbetter: Acts as a statistical consultant to many pharmaceutical and device companies, including those who manufacture products for RA. Tegan Smith: Former employee of OPAL Rheumatology Ltd, current employee of Hunter Medical Research Institute, Newcastle, NSW, Australia. Catherine O’Sullivan: Former employee of OPAL Rheumatology Ltd. Miriam Calao: Employee of AbbVie Pty Ltd. Nicole Walsh: Employee of AbbVie Pty Ltd. and may hold stock or options. Geoffrey Littlejohn: has received honoraria for lectures, presentations, consulting, or support/sponsorship for scientific conferences from AbbVie, AstraZeneca, Gilead, and GSK.
: The activities of OPAL Rheumatology Ltd have received overarching ethics approval from the University of New South Wales Human Research Ethics Committee (HC17799), based on opt-out patient consent. This protocol was approved by the University of New South Wales Human Research Ethics Committee (HC230281). Inclusion of data in the OPAL dataset was based on opt-out consent, all data are de-identified.
